Publicidad
Navicor - An Oncology Focused Advertsing Agency - MedAd News profile
Navicor - An Oncology Focused Advertsing Agency - MedAd News profile
Navicor - An Oncology Focused Advertsing Agency - MedAd News profile
Próximo SlideShare
Optimum LightpathOptimum Lightpath
Cargando en ... 3
1 de 3
Publicidad

Más contenido relacionado

Publicidad
Publicidad

Navicor - An Oncology Focused Advertsing Agency - MedAd News profile

  1. THE MAGAZINE OF PHARMACEUTICAL BUSINESS AND MARKETING • MEDADNEWS.COM • ELECTRONICALLY REPRINTED FROM APRIL 2013 • VOLUME 32 NUMBER 4 AGENCY OF THE YEAR CATEGORY III THE NAVICOR GROUP Navicor marked the end of 2012 with high double-digit growth, the realization of some significant short-term objectives, and its greatest success to date. In all, the agency experienced 39 percent overall growth in 2012, jumping from 48 employees to 73 by year-end.
  2. CATEGORY III—AGENCIES WITH INCOME OF LESS THAN $25 MILLION Posted with permission from MED AD NEWS, April 2013. Copyright 2013 by Canon Communications LLC. All rights reserved. For more information on the use of this content, contact Wright’s Media at 877-652-5295. 100569 nership with Affymax andTakeda, the brand is the first erythropoietin-stimulating agent to be introduced in more than 20 years. As part of the “Bringing Response to Life” campaign for Seattle Genetics and its brand ADCETRIS, the agency built a towering traffic builder of an antibody-drug conjugate from more than 6,000 cans of food at the annual American So- ciety of Hematology meeting. The idea was ini- tially developed by Navicor, and the materials were then donated to nonprofits at the conclu- sion of the show. “It was an incredible win-win while underscoring our benevolent nature as an agency,” Querry says. “Our focus stayed true to the message, not the medium. And with most of our business going high-tech, it was fantastic to draw so much attention for our client at a major convention.” Technology continued to play a ma- jor role in Navicor’s growth in 2012. “We’re ahead of the curve, as more than two-thirds of our business is now digital – with two of our three largest accounts being digital,” says Marvin Bowe, execu- tive creative director. “We realize that even referring to projects as ‘digital’ will soon fade, as that will be a core expecta- tion by every client. We’re already seeing this at almost every juncture. For exam- ple, Navicor produced 17 sales aids for iPads in just the past year alone. That’s incredible.” STRUCTURE AND SERVICES For the ninth straight year, Navicor con- tinued to add to staff. Recent hires in- clude Phil Storer, the agency’s new VP/ digital strategist from sister agency GSW Worldwide. Greg Niemczyk, senior VP/ director of client services from Chicago’s AbelsonTaylor, co-leads the Affymax and Takeda brand Omontys along with Paul Weiss, new VP/creative director, from Corbett Accel Healthcare Group. Susan Yug, senior VP/account services, joined from Euro RSCG and co-leads Millennium’s VELCADE account along with Doug Bierl and Wolf Gallwitz, Ph.D., who are both VP/ account directors who had held lead oncology account positions at GSW Worldwide. Leading the creative team on Millennium’s VELCADE account is Donna Baker, who was recently pro- moted from associate creative director to VP/ creative director. FUTURE PLANS ExecutivessayasNavicorbuildsonthemomen- tum of consecutive successful years, the agency never loses sight of its original commitment to oncology. While its list of core clients expands, significant new objectives have been developed for the coming year and beyond. Most notable, as a part of inVentiv Health Communications, Navicor will soon be integrating the newly cre- ated inVentiv Digital+Innovation group, as well as partnering with Kazaam, inVentiv’s recently acquired digital agency. “Through our ‘Done as One’ model, Navicor will be able to offer our clients a substantially larger ‘virtual’ community of digital talent and expertise,” Bowe says. “Like never before, we will be competing as a formi- dable and global digital expert.” PHILANTHROPY/CITIZENSHIP Navicor considers active participation in phil- anthropic efforts around oncology a major pri- ority. The agency has had a nearly decade-long relationship with The Leukemia & Lymphoma Society. From chili cook-offs to annual Mardi Gras events to “Navi-Q” barbecue events, it has raised more than $54,000 to date for the cause. “We eat well at our fund-raisers,” Querry says. “But I’ve never been associated with a more giv- ing, caring, and amazing group of individuals in my entire career.” 0 MEDADNEWS THIS ARTICLE CAN BE ACCESSED ONLINE AT The Navicor Group LLC 480 Olde Worthington Road, Suite 200 Westerville, OH 43082 Telephone: 614-543-6011 Website: navicorgroup.com Very few agencies began the way The Navicor Group did. When Garnett Dezember’slifewastouchedbycancer,itbecame his personal commitment to create a positive and lasting change in the oncology therapeutic market. Now, nearly nine years later, this group of more than 73 skilled and devoted individuals has achieved tremendous success by transform- ing oncology products into major brands. “And, ultimately that helps transform patients into sur- vivors,” says Dezember, Navicor’s founder and president. By following this mission, Navicor marked the end of 2012 with high double-digit growth, the realization of some significant short- term objectives, and its greatest success to date. THE YEAR’S ACCOMPLISHMENTS Although many agencies recognized growth, 2012 was truly an exceptional year for Navicor. Dezember says while the agency’s expansion is carefully planned, “we are definitely making unprecedented progress in the oncology arena.” In all, the agency experienced 39 percent overall growth in 2012, jumping from 48 employees to 73 by year-end. “Our new business wins were significant, and many without a pitch,” says Dave Querry, executive/managing director. “This tells us that the Navicor name is not only becoming widely recognized in oncology, but also that the many relationships it has built with key individuals are circling back in a very positive fashion.” In 2012, Navicor expanded its business with client Sigma-Tau to include work on Oncaspar and DepoCyt, with OncoGenex for work on OGX-427, and with Takeda for the global launch of Omontys. New clients added to Navicor’s roster include NanoString for work on its global launch of Prosigna and Teva Pharmaceuticals for work on its disease education platform for Custirsen. Campaign projects played a prominent role with many of Navicor’s largest accounts. In Oc- tober, following an expedited approval launch, the agency launched the “Reducing the Bur- den” campaign for Omontys. Produced in part- AGENCY OF THE YEAR ACCOUNTS Account wins 6 Active business clients 9 BRANDS BY 2012 SALES Brand-product accounts held 8 $25 million or less 1 $25 million - $50 million 1 $50 million - $100 million 1 $100 million - $500 million 1 $500 million to $1 billion 1 Digital 60% Advertising 40% Affymax, Inc./Takeda Pharmaceuticals U.S.A., Inc. Millennium: The Takeda Oncology Company NanoString Technologies OncoGenex Seattle Genetics, Inc. Sigma-Tau Pharmaceuticals, Inc. Takeda Teva Oncology SERVICES MIXSERVICES MIXSERVICES MIX QUICK FACTSQUICK FACTSQUICK FACTS CLIENT ROSTERCLIENT ROSTERCLIENT ROSTER WINNERWINNERWINNER (left to right) Marvin Bowe, senior VP, executive creative director; LeAnn Duncan-Miller, VP, resource management; Brent Bernstein, senior VP, account services; Carmella Abraham, M.D., VP, medical director; Dave Querry, executive VP, managing director; Greg Niemczyk, senior VP, director of client services; Rich D’Ginto, senior VP, creative director; Garnett Dezember, president. “Living Proof” takes wonderful moments that make patients laugh, love, and live and conveys them in words within the life lines of a beautiful, aging face. “Bringing Response to Life,” through proper balance of emotion and science, uses this CT scan to show the ADCETRIS response rate being fully realized.
  3. Urgent need!Subject: Hey Tom, Can you come in and teach us about multiple myeloma? THE ONCOLOGY AGENCY Is this what you expected when you sent the RFP? You can expect more from Navicor. We know oncology. We understand cancer better than any general health care agency. Howdoweknow? Our folks are the ones receiving late-night recruiting calls from other agencies. At The Navicor Group, we specialize in just one area: oncology. And for years, we’ve been helping to promote, maintain, and globally launch some of the most successful brands in oncology. Our team of oncology experts and medical specialists partner every day with award-winning creative professionals to produce strategies and tactics that help turn oncology products into important brands— and patients with cancer into survivors. So if you are looking for specialized knowledge and understanding specific to oncology, you’re looking for The Navicor Group. Contact Dave Querry @ 614.543.6466 | navicorgroup.com 7:31 PM Tuesday—Still searching for an oncology “consultant” for the pitch 5:47 PM Monday—Agency receives RFP
Publicidad